克唑替尼用于难治性ALK阳性淋巴瘤的治疗
[Use of crizotinib for refractory ALK-positive lymphomas].
作者信息
Shelikhova L N, Fominykh V V, Abramov D S, Myakova N V, Maschan M A, Maschan A A
机构信息
Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia.
出版信息
Ter Arkh. 2017;89(7):51-56. doi: 10.17116/terarkh201789751-56.
AIM
To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL).
SUBJECTS AND METHODS
The paper describes the experience with crizotinib used in 8 patients with refractory ALK-ALCL before and after allogeneic hematopoietic stem cell transplantation (HSCT).
RESULTS
All the 8 (100%) patients treated with crizotinib were recorded to have complete responses, including complete metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography.
CONCLUSION
Low and manageable toxicity of crizotinib and complete PET-negative responses in patients with resistant ALK lymphomas favor the need to test the drug as first-line therapy, by possibly decreasing the intensification of chemotherapy.
目的
评估克唑替尼用于复发或难治性ALK阳性间变性大细胞淋巴瘤（ALCL）儿科患者的安全性和有效性。
对象与方法
本文描述了8例难治性ALK-ALCL患者在异基因造血干细胞移植（HSCT）前后使用克唑替尼的经验。
结果
所有8例（100%）接受克唑替尼治疗的患者均有完全缓解记录，包括完全代谢缓解（正电子发射断层扫描（PET）/计算机断层扫描显示肿瘤消失）。
结论
克唑替尼毒性低且可控，耐药性ALK淋巴瘤患者PET完全阴性反应表明，可能通过降低化疗强度，有必要将该药物作为一线治疗进行试验。
Zotero 插件